| Keywords: |
cancer chemotherapy; clinical trial; cisplatin; doxorubicin; drug potentiation; monotherapy; antineoplastic agents; note; adjuvant therapy; cancer radiotherapy; follow up; antineoplastic agent; clinical practice; neoplasm; neoplasms; carboplatin; controlled clinical trial; multiple cycle treatment; breast cancer; nausea; randomized controlled trial; vomiting; editorial; combination chemotherapy; cyclophosphamide; dexamethasone; practice guideline; pathology; chemotherapy induced emesis; drug antagonism; drug mechanism; drug combination; drug therapy, combination; add on therapy; chemically induced disorder; morpholines; serotonin antagonist; granisetron; ondansetron; nausea and vomiting; antiemetic agent; antiemetics; metoclopramide; clinical trials; aprepitant; neurokinin 1 receptor; dolasetron mesilate; palonosetron; receptors, neurokinin-1; morpholine derivative; humans; human; priority journal; tachykinin receptor antagonist
|
